Tumor Infiltrating Lymphocyte Biology

Solutions Accelerated by IsoPlexis

  • Combination Cancer Therapies

Apply TILs PSI as a correlate to response in combination checkpoint therapy1

Uncover the polyfunctional T cell subsets which correlate to in vivo activity and identify biomarker correlates to response in solid tumor therapies.

Download application highlight

Research Area

Development Stage



Uncovering the ability to predict adaptive resistance to glioblastoma and other solid tumors to targeted inhibitor therapeutics.

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell


IsoPlexis’ PSI successfully stratifies patient responders and non-responders

polyfunctional cell


Polyfunctional strength uniquely correlated with response, while histology and serum cytokine measurements did not

follow our data

Follow Our Data

See the latest published data in Solid Tumor & Oncology

Single cell polyfunctionality shows positive correlation with clinical anti-tumor responses after treatment. Samples from responders have 9x more polyfunctional cells than non-responders, and 40x higher polyfunctional strength (p= 0.0294).

Individual cells secreted various combinations of effector cytokines (Granzyme B, IFN-γ, MIP-1α, Perforin and TNF-α) associated with anti-tumor immunity.1

Download application highlight
Polyfunctional Strength


Detect Critical Differences

PSI as a biomarker outperformed other measured metrics. Single-Cell PSI of CD8+ TILs significantly correlates with outcome of anti-PD-1/CTLA4 treated patients with metastatic melanoma.

No significant association was identified between clinical outcome and other measurements, including TILs % by histopathological assessment or serum concentration.1

PSI, TILs, Cytokine Concentration

Request a Seminar

Request a Seminar
Discover IsoLight